CPP’s trial involved a total of 171 patients, making it the largest ever created for this condition. It was also the longest trial ever conducted for FAP.
Specifically, the trial compared the combination of CPP-1X with sulindac with sulindac and CPP-1X on their own. You can read more about the specifics of the trial here.
If everything stays on schedule, we should hear the results of this trial very shortly. If approved, this drug could significantly improve not only outcomes for FAP patients, but their quality of life.
You can read more updates on CPP and this trial here.